CDC ENTEBBE

A late-stage clinical trial showed liraglutide, similar to Ozempic, reduced BMI in kids ages 6-11 with obesity, with concerns about long-term safety and impact on growth. The trial included 82 children, with liraglutide resulting in a 5.8% average BMI reduction compared to a 1.6% increase in the placebo group. Novo Nordisk has applied to the FDA for approval of liraglutide for weight loss in this age group.

FDA found psychoactive substances in Diamond Shruumz products, causing 158 illnesses, 63 hospitalizations, and 2 deaths. Recalled products include Dark Chocolate Bar and Birthday Cake Chocolate Bar, containing 4-acetoxy-DMT, desmethoxyyangonin, dihydrokavain, and kavain. FDA advises avoiding all Diamond Shruumz products.

Zydus completes Phase II(a) study of NLRP3 inhibitor 'Usnoflast (ZYIL1)' in ALS patients, reporting therapeutic concentrations in CSF and reduced neurofilaments, with improvements in ALSFRS-R score and SVC. The study involved 24 ALS patients across 7 sites in India and will proceed to a larger Phase 2b trial. Usnoflast, an oral small molecule, has shown efficacy in pre-clinical models of neuroinflammation, Parkinson’s, IBD, and MS, and has received USFDA Orphan Drug Designation for CAPS treatment.

Zydus Lifesciences completes Phase II(a) trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor for ALS, showing proof-of-concept, favorable safety, and trends towards reduction in neurodegeneration biomarkers.

Zydus Lifesciences completes Phase II(a) trial of Usnoflast, an oral NLRP3 inflammasome inhibitor for ALS, showing therapeutic concentrations in CSF and reduced neurofilaments, with encouraging improvements in ALSFRS-R score and SVC.

Zydus Lifesciences announced successful completion of Phase II(a) trial for Usnoflast, an NLRP3 inflammasome inhibitor, in ALS patients. The trial showed Usnoflast's safety, ability to reach therapeutic levels in blood and spinal fluid, and reduction of Neurofilament Light chain levels, suggesting potential benefits for neurodegenerative conditions. Improvements in ALS Functional Rating Scale and Slow Vital Capacity scores indicate Usnoflast may slow ALS progression.

Older adults should get the 2024–25 flu vaccine by early October. Specialized vaccines like Fluzone High-Dose, Fluad adjuvanted, and Flublok recombinant offer enhanced protection, with Medicare covering most. Side effects may be more common with high-dose shots.

Make America Healthy Again PAC, founded by ex-RFK Jr. campaign staff, urges supporters to vote Trump to bring RFK Jr.'s policies to forefront. PAC aims to align RFK Jr.'s policies with Trump's leadership, focusing on health, agriculture, and corruption. Kennedy may join Trump's administration if elected.

LEVI-04, a novel neurotrophin-3 inhibitor, demonstrated a 50% reduction in pain for osteoarthritis patients with no adverse effects, in a Phase II study.